World's Best Scientists 2026 revealed!
Alexander M.M. Eggermont

Alexander M.M. Eggermont

D-Index & Metrics

Medicine

D-Index
144
Citations
103864
World Ranking
1412
National Ranking
31

Overview

Alexander M.M. Eggermont is affiliated with the Institut Gustave Roussy in France. Their research primarily focuses on the field of Medicine, with significant contributions specifically in Oncology, Immunology, Molecular Biology, Epidemiology, and Pulmonary and Respiratory Medicine.

The scientist's work spans several main topics, including:

  • Cutaneous Melanoma Detection and Management
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Nonmelanoma Skin Cancer Studies
  • Cancer Genomics and Diagnostics

Alexander M.M. Eggermont has published extensively in prominent venues. The most frequent publication venues include:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • The Lancet Oncology
  • Annals of Oncology
  • Molecular Oncology

Frequent co-authors in their research include:

  • Georgina V. Long
  • Paolo A. Ascierto
  • Caroline Robert
  • Dirk Schadendorf
  • Mario Mandalà

Some of the recent papers authored or co-authored by Alexander M.M. Eggermont include:

  • "Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo," 2020, JAMA Oncology
  • "Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial," 2020, Journal of Clinical Oncology
  • "The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes," 2020, Cancer Cell (authored by Floris Dammeijer as primary author with Eggermont likely involved)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment," 2020, European Journal of Cancer (Authored by Alexander Stratigos)
  • "European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention," 2020, European Journal of Cancer (Authored by Alexander J. Stratigos)

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

    Marie Vétizou;Marie Vétizou;Marie Vétizou;Jonathan M. Pitt;Jonathan M. Pitt;Jonathan M. Pitt;Romain Daillère;Romain Daillère;Romain Daillère;Patricia Lepage

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean Jacques Grob;Reinhard Dummer

  • Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

    J.M. Pitt;A. Marabelle;A. Marabelle;A. Eggermont;J.-C. Soria

  • Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

    N. Chaput;P. Lepage;C. Coutzac;C. Coutzac;E. Soularue;E. Soularue

  • Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

    Stephane Champiat;Stephane Champiat;Laurent Dercle;Samy Ammari;Christophe Massard

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

    Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

    Remco van Horssen;Timo L. M. ten Hagen;Alexander M. M. Eggermont

  • Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

    S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

Frequent Co-Authors

Caroline Robert
Caroline Robert University of Paris-Saclay
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Guido Kroemer
Guido Kroemer Université Paris Cité
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Lorenzo Galluzzi
Lorenzo Galluzzi Cornell University
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Axel Hauschild
Axel Hauschild Kiel University
Ulrich Keilholz
Ulrich Keilholz Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare degrees and career pathways can offer flexible entry points into the medical field in the USA. If you're interested in becoming a nurse but hold a bachelor’s degree in another subject, consider msn direct entry programs online designed for non-nurses. These accelerated master's programs allow you to qualify as a registered nurse in less time.

For students seeking accessible options, there are nursing programs with high acceptance rates. These can be a practical starting point if competitive admissions are a concern. Additionally, financial and entrance exam barriers can be minimized by looking for absn programs that don't require teas, opening opportunities for more prospective students.

Interested in healthcare administration? Explore accredited medical billing and coding schools online with financial aid to gain essential skills for this growing field. Each of these pathways can help you carve out a rewarding career in healthcare while allowing for greater flexibility and accessibility.

Best Scientists Citing Alexander M.M. Eggermont

Trending Scientists